Automatic Oxygen Control for Reducing Extremes of Oxygen Saturation (AreOS): A Randomised Control Trial

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Prematurity
Interventions
DEVICE

Automatic Oxygen control

The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.

OTHER

Manual Oxygen Control

In the manual arm the oxygen is adjusted manually by the clinical team.

Trial Locations (1)

TS4 3BW

South Tees NHS Trust, Middlesbrough

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vyaire Medical

INDUSTRY

lead

South Tees Hospitals NHS Foundation Trust

OTHER

NCT04223258 - Automatic Oxygen Control for Reducing Extremes of Oxygen Saturation (AreOS): A Randomised Control Trial | Biotech Hunter | Biotech Hunter